Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PCNAT-01
- Development stage
- Phase 1
- Lead developer
- Anda Biopharmaceutical Development Co., Ltd.
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous, Intramuscular
01
Overview
PCNAT-01 is a personalized neoantigen peptide-based cancer vaccine developed by Anda Biopharmaceutical Development (Shenzhen) Co., Ltd. It is designed as an immunotherapy for pancreatic cancer, specifically targeting pancreatic ductal adenocarcinoma. The vaccine leverages next-generation sequencing and major histocompatibility complex affinity prediction algorithms to identify patient-specific tumor neoantigens, which are then formulated into individualized peptide vaccines. Its mechanism of action involves stimulating the immune system—particularly cytotoxic CD4 and CD8 T cells—to recognize and attack tumor cells expressing these unique neoantigens. Early-phase clinical trials have demonstrated favorable safety profiles and promising recurrence-free and overall survival rates in patients following surgical resection and adjuvant chemotherapy[1][2][4][5].
- Other names
- Personalized neoantigen peptide-based vaccinePersonalized neoantigen vaccine
02
Targets
Human leukocyte antigen class I and II moleculespMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on PCNAT-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PCNAT-01.